Medications
|
Date
started
|
||||||
0
|
14
|
21
|
28
|
||||
Progynova [28’s] (Estradiol Valerate)
|
|||||||
·
HRT for
symptoms secondary to oestrogen deficiency due to natural menopause or
castration.
·
Prevention of
menopausal osteoporosis.
|
Estradiol Valerate
|
||||||
Femoston [28’s] (Estradiol 1mg and dydrogesterone
10 mg)
|
|||||||
·
HRT in
naturally/ surgically induced menopause with intact uterus.
|
Estradiol 1 mg
|
Estradiol 1mg, dydrogesterone 10 mg
|
|||||
Menorest [28’s] (Tibolone 2.5 mg)
|
|||||||
·
Menopause
symptoms contraindicated / intolerant to other treatments.
|
Tibolone 2.5 mg
|
||||||
Loette [21’s] (Levonorgestrel 100 mcg,
Ethinylestradiol 20 mcg)
|
|||||||
·
Contraception
·
Moderate acne
non-responsive to conventional therapy in premenarchal, premenopausal women ≥ 14 years old.
·
Non-contraceptive
benefits:
|
Levonorgestrel 100 mcg,
Ethinylestradiol 20 mcg
|
-
|
|||||
Progyluton [21’s] (Estradiol 2 mg and Norgestrel
0.5 mg)
|
|||||||
·
Treatment of
oestrogen deficiency secondary to menopause, hypogonadism, castration or
primary ovarian failure in women with intact uterus.
·
Prevention of
postmenopausal osteoporosis.
·
Control of
irregular menstrual cycle.
·
Treatment of
primary and secondary amenorrhea.
|
Estradiol 2 mg (10d)
|
Estradiol 2 mg,
Norgestrel 0.5 mg (11d)
|
-
|
||||
Premarin [28’s] (Conjugated oestrogen 0.3 mg or
0.625 mg)
|
|||||||
·
Oestrogen
deficiency in females (0.3-1.25 mg OD)
·
Osteoporosis
(0.3 mg OD).
·
Vasomotor
symptoms, atrophic vaginitis and atrophic urethritis associated with
hypoestrogenism. (Topical preferred) (0.3-1.25 mg OD).
|
Conjugated oestrogen
|
||||||
Ravimed (Medroxyprogesterone Acetate 5 mg)
|
|||||||
Renal cell &
endometrial carcinoma
|
200- 400 mg
OD
|
||||||
Breast carcinoma
|
500 mg OD
|
||||||
Endometriosis
|
10 mg TDS X 90 days
|
||||||
Abnormal uterine bleeding/
secondary amenorrhea
|
2.5- 10 mg X 10/7
Continue for 3 consecutive
cycles.
|
||||||
2.5- 10 mg X 5/7
Continue for 3 consecutive
cycles.
|
|||||||
Adjunct of cyclic
oestrogen therapy
|
10- 20 mg OD for the last
7 days of each cycle.
|
||||||
Table1: Administration of Hormonal Therapies
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.